60
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

, , , , , , , , , , , , , & show all
Pages 677-686 | Published online: 16 Feb 2016

Figures & data

Table 1 Patient characteristics

Figure 1 Indications for pre-transplant use of amiodarone.

Notes: Indications for long-term amiodarone therapy were atrial fibrillation in ten patients (13.5%), Wolff–Parkinson–White syndrome in one patient (1.4%), ventricular tachycardia in 57 patients (77.0%), and ventricular fibrillation in six patients (8.1%).
Figure 1 Indications for pre-transplant use of amiodarone.

Table 2 Initial post-transplant medication

Table 3 Influence of long-term use of amiodarone on early post-transplant atrial fibrillation

Figure 2 Kaplan–Meier estimator (freedom from early post-transplant atrial fibrillation).

Note: Freedom from early post-transplant atrial fibrillation (≤30 days after HTX) in patients with/without pre-transplant use of amiodarone.
Abbreviations: HTX, heart transplantation; AF, atrial fibrillation.
Figure 2 Kaplan–Meier estimator (freedom from early post-transplant atrial fibrillation).

Table 4 Influence of long-term use of amiodarone on mortality after HTX

Figure 3 Kaplan–Meier estimator (overall follow-up survival).

Note: Survival of patients with/without pre-transplant use of amiodarone.
Abbreviation: HTX, heart transplantation.
Figure 3 Kaplan–Meier estimator (overall follow-up survival).